论文部分内容阅读
2016年8月,欧洲心脏病学会发布了肿瘤心脏病学领域首部用于指导临床实践的纲领性文件——《2016欧洲心脏病学会癌症治疗与心血管毒性立场声明》。该声明对肿瘤治疗相关心肌功能不全与心力衰竭、冠状动脉疾病、心脏瓣膜病、心律失常、高血压、血栓栓塞性疾病、周围血管病与卒中、肺动脉高压及心包并发症等病的发病机制、临床评估与管理、预防缓解策略及长期随访流程进行了详细推荐。作者结合国内外现有文献,对声明的主要内容进行解读。
In August 2016, the European Society of Cardiology released the first programmatic document in the field of oncology cardiology to guide clinical practice - “The European Society of Cardiology 2016 Cancer Statement and Cardiovascular Toxicity Statement.” This statement addresses the pathogenesis of cancer-related myocardial dysfunction and heart failure, coronary artery disease, valvular heart disease, arrhythmia, hypertension, thromboembolic disease, peripheral vascular disease and stroke, pulmonary hypertension and pericardial complications, Clinical evaluation and management, prevention and mitigation strategies and long-term follow-up process were recommended in detail. The author combines the existing literature at home and abroad to interpret the main contents of the statement.